Published in J Antimicrob Chemother on August 02, 2006
Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter? Crit Care (2009) 1.11
Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers. Int Arch Med (2008) 0.93
Determinants of intrinsic aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2012) 0.88
Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions. PLoS One (2013) 0.87
National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations. J Pediatr Pharmacol Ther (2011) 0.85
Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load? PLoS One (2013) 0.84
Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics. Int J Antimicrob Agents (2013) 0.82
Improved outcomes of patients with end-stage cystic fibrosis requiring invasive mechanical ventilation for acute respiratory failure. Lung (2011) 0.82
Evaluation of serum concentrations achieved with an empiric once-daily tobramycin dosage regimen in children and adults with cystic fibrosis. J Pediatr Pharmacol Ther (2012) 0.80
Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients. Clin Microbiol Rev (2014) 0.79
Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa. J Antimicrob Chemother (2016) 0.78
A Bayesian Modelling Approach with Balancing Informative Prior for Analysing Imbalanced Data. PLoS One (2016) 0.77
Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation. Antimicrob Agents Chemother (2013) 0.76
A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill Patients. Antimicrob Agents Chemother (2015) 0.76
Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A Pharmacist Approach. J Pediatr Pharmacol Ther (2016) 0.75
Extended-Interval Aminoglycoside Use in Cystic Fibrosis Exacerbation in Children and Young Adults: A Prospective Quality Improvement Project. Glob Pediatr Health (2016) 0.75
Acute renal failure in people with cystic fibrosis. Thorax (2007) 0.75
Once daily dosing of aminoglycosides in pediatric cystic fibrosis patients: a review of the literature. J Pediatr Pharmacol Ther (2008) 0.75
Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med (2008) 19.93
Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol (2008) 3.06
Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med (2007) 2.97
Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med (2012) 2.86
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother (2005) 2.50
Practice and perception--a nationwide survey of therapy habits in sepsis. Crit Care Med (2008) 2.43
Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis (2010) 2.37
Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist (2009) 2.37
Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet (2006) 2.32
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev (2012) 2.31
Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. J Clin Pharmacol (2008) 2.22
Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. Clin Infect Dis (2008) 2.20
Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med (2010) 2.19
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Evid Based Child Health (2013) 2.12
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother (2004) 2.10
Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med (2007) 2.06
Tissue concentrations: do we ever learn? J Antimicrob Chemother (2007) 1.92
Fluid replacement with hydroxyethyl starch in critical care--a reassessment. Dtsch Arztebl Int (2013) 1.87
Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth. FASEB J (2004) 1.74
Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment. Am J Med (2008) 1.70
Resident alveolar macrophages are replaced by recruited monocytes in response to endotoxin-induced lung inflammation. Am J Respir Cell Mol Biol (2006) 1.70
Nanoparticle-based diagnosis and therapy. Curr Drug Targets (2006) 1.70
Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis (2012) 1.67
Hospital Incidence and Mortality Rates of Sepsis. Dtsch Arztebl Int (2016) 1.65
Adult patients with nosocomial pneumonia: epidemiology, diagnosis, and treatment. Dtsch Arztebl Int (2013) 1.65
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother (2004) 1.64
Long-term outcome after pulmonary retransplantation. J Thorac Cardiovasc Surg (2006) 1.59
New horizons in early stage COPD--improving knowledge, detection and treatment. Respir Med (2011) 1.56
Protease-activated receptor-1 in human lung fibroblasts mediates a negative feedback downregulation via prostaglandin E2. Am J Physiol Lung Cell Mol Physiol (2004) 1.53
Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents (2008) 1.52
C1-esterase-inhibitor for primary graft dysfunction in lung transplantation. Transplantation (2014) 1.49
α-1-antitrypsin inhibits acute liver failure in mice. Hepatology (2014) 1.49
Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med (2015) 1.48
Protein binding: do we ever learn? Antimicrob Agents Chemother (2011) 1.46
Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. Eur Respir J (2013) 1.45
Bronchiectasis--diagnosis and treatment. Dtsch Arztebl Int (2011) 1.43
Macrophage Turnover Kinetics in the Lungs of Mice Infected with Streptococcus pneumoniae. Am J Respir Cell Mol Biol (2007) 1.42
Lung-specific overexpression of CC chemokine ligand (CCL) 2 enhances the host defense to Streptococcus pneumoniae infection in mice: role of the CCL2-CCR2 axis. J Immunol (2007) 1.41
Allogeneic CD4+CD25high T cells regulate obliterative bronchiolitis of heterotopic bronchus allografts in both porcinized and humanized mouse models. Transplantation (2015) 1.40
Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis (2009) 1.40
PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother (2010) 1.38
Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci (2010) 1.37
How important are gender differences in pharmacokinetics? Clin Pharmacokinet (2002) 1.37
Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ (2003) 1.37
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Pivotal role of cathepsin K in lung fibrosis. Am J Pathol (2004) 1.35
Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med (2015) 1.34
Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother (2006) 1.34
Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung. J Thorac Cardiovasc Surg (2006) 1.33
The discovery of α1-antitrypsin and its role in health and disease. Respir Med (2011) 1.30
Inter-disease comparison of research quantity and quality: bronchial asthma and chronic obstructive pulmonary disease. J Asthma (2009) 1.28
Important role for CC chemokine ligand 2-dependent lung mononuclear phagocyte recruitment to inhibit sepsis in mice infected with Streptococcus pneumoniae. J Immunol (2009) 1.27
Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur Respir J (2011) 1.26
Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers. J Agric Food Chem (2006) 1.26
Health-related quality of life in two hundred-eighty lung transplant recipients. J Heart Lung Transplant (2005) 1.25
Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet (2010) 1.25
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents (2002) 1.24
Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol (2011) 1.23
Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage recruitment in response to pneumococcal lung infection. Infect Immun (2010) 1.23
Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents (2002) 1.23
Nanomedicine for respiratory diseases. Eur J Pharmacol (2006) 1.23
Correlation between chronic obstructive pulmonary disease and obstructive sleep apnea syndrome in a general population in Iran. J Res Med Sci (2011) 1.22
Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study. Thorax (2011) 1.22
Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection. Crit Care (2011) 1.21
Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med (2010) 1.21
Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ (2012) 1.20
Duffy antigen modifies the chemokine response in human endotoxemia. Crit Care Med (2008) 1.20
Analysis of research output parameters: density equalizing mapping and citation trend analysis. BMC Health Serv Res (2009) 1.19
The inflammatory versus constitutive trafficking of mononuclear phagocytes into the alveolar space of mice is associated with drastic changes in their gene expression profiles. J Immunol (2005) 1.19
Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation (2009) 1.17
Altered expression of membrane-bound and soluble CD95/Fas contributes to the resistance of fibrotic lung fibroblasts to FasL induced apoptosis. Respir Res (2005) 1.17
The pulmonary immune effects of mechanical ventilation in patients undergoing thoracic surgery. Anesth Analg (2005) 1.16
Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob Agents Chemother (2008) 1.16
Cost analyses of community-acquired pneumonia from the hospital perspective. Chest (2005) 1.15
Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev Anti Infect Ther (2005) 1.14
Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int J Antimicrob Agents (2006) 1.13
Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res (2009) 1.12
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J (2012) 1.11
Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept. Arthritis Rheum (2002) 1.11
Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents (2005) 1.11
Tobacco smoke exposure induces nicotine dependence in rats. Psychopharmacology (Berl) (2009) 1.11
Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest (2005) 1.11
Burden and trends of hospitalisations associated with pulmonary non-tuberculous mycobacterial infections in Germany, 2005-2011. BMC Infect Dis (2013) 1.10
Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol (2006) 1.10
Role of Mincle in alveolar macrophage-dependent innate immunity against mycobacterial infections in mice. J Immunol (2012) 1.10
Hostile takeover by Plasmodium: reorganization of parasite and host cell membranes during liver stage egress. PLoS Pathog (2011) 1.09
Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother (2006) 1.09
Evolution and architecture of the inner membrane complex in asexual and sexual stages of the malaria parasite. Mol Biol Evol (2012) 1.09
Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection. Am J Respir Crit Care Med (2007) 1.09
Multicentre European study for the treatment of advanced emphysema with bronchial valves. Eur Respir J (2012) 1.09
Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS One (2013) 1.08
Fluoroquinolone-resistant Streptococcus pneumoniae. Emerg Infect Dis (2006) 1.08
Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents (2009) 1.08
ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells. Am J Physiol Lung Cell Mol Physiol (2003) 1.08
Scientometric analysis and combined density-equalizing mapping of environmental tobacco smoke (ETS) research. PLoS One (2010) 1.08
TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. J Exp Med (2012) 1.08
Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol (2004) 1.07